TNFSF13B and myeloid sarcoma: The pivotal phase II trial of atacicept, an anti-BAFF/APRIL agent, was terminated early due to increased disease activity and relapses in treated patients, highlighting the complexity of BAFF’s role in MS pathogenesis [25, 26].